ABS-201 is a groundbreaking hair loss injectable developed by Absci, a company based in Vancouver, Washington, that is leveraging AI to create revolutionary new medications. ABS-201 targets the prolactin receptor, a protein that typically plays a role in mammary development. Unlike other hair loss treatments like minoxidil and hair transplants, ABS-201 doesn’t just prevent further hair loss, it encourages hair regrowth.

BS-201 works by shunting the dormant hair follicles back into a different phase of the hair cycle called the anagen phase. No other drugs target the prolactin receptor in the same way, says Anthony Rossi, MD, a dermatologist at the Memorial Sloan Kettering Cancer Center, which partners with Absci.

ABS-201 is part of a burgeoning new trend in revolutionary hair loss treatments. For instance, a 2024 study published in the journal Frontiers in Pharmacology proposed using deoxy-ribose sugars—or the substance that makes up the backbone of DNA—as a topical hair regrowth treatment. In another study, published in Nature Cell Biology this year, researchers propose a medication called PP405, which wakes up “sleepy hair follicles,” which would focus on the follicles’ metabolism. Both treatment options proved to be promising in their respective trials, though they are not yet available on the market
 
The rise of GLP-1s—or injectable medications that manage Type 2 diabetes and obesity—may have “opened up the path” for injectable biologics like ABS-201, explains Sean McClain, founder and CEO of Absci. Injectables correct a major flaw of topical and oral interventions: forgetfulness. Most hair loss treatments must be administered every day, whether it be through a pill or an ointment. Injectables, like ABS-201, offer convenient dosing, so patients only need to remember a shot every few months.

@nexta_tv
Baldness — over: scientists have created a serum that restores hair in just 20 days
 
Researchers in Taiwan tested a new formula on mice — and within three weeks, completely bald animals started growing fur again.
 
The secret lies in natural fatty acids that stimulate hair follicles without irritating the skin. Scientists say the serum is safe and are preparing for human trials.
 
Looks like Turkey might soon see fewer bald tourists.
 

a method of directly waking up hair follicle stem cells without touching hormones like dutasteride and finasteride

Cosmo Pharmaceuticals has reported encouraging topline findings from 2 large, identically designed phase 3 trials evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). If ultimately approved, the drug could represent the first new therapeutic mechanism for AGA in over 30 years—a notable development for a condition with high prevalence and limited treatment options.

Clascoterone 5% topical solution employs a different approach: local androgen receptor inhibition at the follicular level, designed to reduce DHT signaling without meaningful systemic absorption. This mechanism may appeal to patients who avoid oral treatments due to concerns about hormonal effects or other systemic adverse events.

Both trials demonstrated statistically significant improvements in hair growth compared with vehicle. In one study, clascoterone produced a 5.39-fold (539%) relative improvement in TAHC, while the second trial showed a 1.68-fold (168%) relative improvement. The magnitude of difference between the 2 studies is not unusual for hair-growth research, which often shows variability based on baseline disease severity, regional demographics, or site-level differences in assessment technique.
 
Importantly, PRO data reinforced the objective findings. One study met its PRO endpoint while the other demonstrated a positive trend; combined analysis across both trials achieved statistical significance. Alignment between patient perception and investigator-assessed improvement is clinically relevant, particularly in a condition where self-image and treatment satisfaction play a central role in adherence.

Cosmo plans to complete the required 12-month safety follow-up by spring 2026, after which parallel FDA and EMA submissions are expected. If approved, clascoterone 5% solution would become the first topical androgen receptor inhibitor indicated for AGA.

Peux-tu estimer la date de disponibilité probable du Clascoterone 5% pour combattre la calvouze ?

D'après les informations récentes sur le développement du Clascoterone 5 % (également connu sous le nom de Breezula pour le traitement de l'alopécie androgénétique), les essais cliniques de phase 3 ont montré des résultats positifs en décembre 2025, avec une amélioration significative de la densité capillaire chez les hommes. Les données de suivi de sécurité sur 12 mois devraient être finalisées au printemps 2026, suivies de soumissions réglementaires parallèles à la FDA (États-Unis) et à l'EMA (Europe).
Compte tenu des délais typiques d'examen réglementaire (environ 10-12 mois pour une approbation standard par la FDA, et similaire pour l'EMA), l'approbation pourrait intervenir vers mi-2027. La disponibilité commerciale, y compris en France, dépendrait ensuite de la finalisation des processus d'approbation et de distribution, ce qui pourrait porter la date probable à fin 2027 ou début 2028 dans le pire des cas. Notez que ces essais portent principalement sur les hommes, et que le produit n'est pas encore approuvé pour cet usage (il l'est déjà à 1 % pour l'acné sous le nom Winlevi). Si des avancées accélérées surviennent (par exemple, une revue prioritaire), cela pourrait avancer légèrement, mais c'est une estimation basée sur les timelines actuelles.